These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17266685)

  • 1. The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus--the good, the bad, and the flawed!
    Leedham S; Jankowski J
    Am J Gastroenterol; 2007 Jan; 102(1):21-3. PubMed ID: 17266685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
    Jankowski JA; Anderson M
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acid suppression and chemoprevention in Barrett's oesophagus.
    Raj A; Jankowski J
    Dig Dis; 2004; 22(2):171-80. PubMed ID: 15383758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
    Sharma P; Sampliner RE; Camargo E
    Am J Gastroenterol; 1997 Apr; 92(4):582-5. PubMed ID: 9128303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medical treatment of Barrett's esophagus].
    Kinoshita Y; Yuki T
    Nihon Rinsho; 2005 Aug; 63(8):1449-53. PubMed ID: 16101238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
    Ortiz A; Martínez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
    Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
    Todd JA; Basu KK; de Caestecker JS
    Aliment Pharmacol Ther; 2005 Apr; 21(8):969-75. PubMed ID: 15813832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical strategy for the Barrett's esophagus].
    Kitabatake S; Niwa Y; Goto H
    Nihon Rinsho; 2005 Aug; 63(8):1434-7. PubMed ID: 16101235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy.
    El-Serag HB; Aguirre T; Kuebeler M; Sampliner RE
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1255-60. PubMed ID: 15191506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors for squamous re-epithelialization of Barrett's esophagus after endoscopic biopsy.
    Amano Y; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Ishimura N; Furuta K; Ishihara S; Adachi K; Maruyama R; Kinoshita Y
    J Gastroenterol Hepatol; 2007 Jun; 22(6):901-7. PubMed ID: 17565646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barrett's esophagus: chemoprevention.
    Souza RF; Spechler SJ
    Gastrointest Endosc Clin N Am; 2003 Jul; 13(3):419-32. PubMed ID: 14629099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett's oesophagus.
    Abu-Sneineh A; Tam W; Schoeman M; Fraser R; Ruszkiewicz AR; Smith E; Drew PA; Dent J; Holloway RH
    Aliment Pharmacol Ther; 2010 Oct; 32(8):1023-30. PubMed ID: 20937048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use.
    Siersema PD; Yu S; Sahbaie P; Steyerberg EW; Simpson PW; Kuipers EJ; Triadafilopoulos G
    Gastrointest Endosc; 2006 Apr; 63(4):581-6. PubMed ID: 16564855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression?
    Fennerty MB
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S30-7. PubMed ID: 12478242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical treatment of Barrett's esophagus: can it prevent cancer?
    Sampliner RE
    Surg Oncol Clin N Am; 2009 Jul; 18(3):503-8. PubMed ID: 19500739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention of adenocarcinoma associated with Barrett's esophagus: potential options.
    Neumann H; Mönkemüller K; Vieth M; Malfertheiner P
    Dig Dis; 2009; 27(1):18-23. PubMed ID: 19439956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is symptom control the correct end point for proton pump inhibitor treatment in Barrett's oesophagus?
    Sarela AI; Verbeke CS; Pring C; Guillou PJ
    Gut; 2004 Sep; 53(9):1387-8. PubMed ID: 15306606
    [No Abstract]   [Full Text] [Related]  

  • 20. In Barrett's epithelial cells, weakly acidic bile salt solutions cause oxidative DNA damage with response and repair mediated by p38.
    Huo X; Dunbar KB; Zhang X; Zhang Q; Spechler SJ; Souza RF
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G464-G478. PubMed ID: 31984785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.